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Summary
The lankacidin biosynthetic gene cluster in Strepto-
myces rochei strain 7434AN4 was found to span 31
kb of the giant linear plasmid pSLA2-L and contain a
polyketide synthase (PKS)/nonribosomal peptide syn-
thetase (NRPS) hybrid gene (lkcA), type I PKS genes,
and pyrroloquinoline quinone (PQQ) biosynthetic
genes (lkcK-lkcO). Feeding of PQQ to a pqq mutant
restored the lankacidin production, suggesting its
crucial role in an oxidation process. However, forma-
tion of the 17-membered macrocyclic ring was not
catalyzed by PQQ-dependent dehydrogenase (Orf23),
but was by flavin-dependent amine oxidase (LkcE).
Compound LC-KA05 isolated from an lkcE disruptant
was an acyclic intermediate lacking the C2-C18 link-
age. These results suggested a cyclization mecha-
nism for the synthesis of the lankacidin macrocyclic
skeleton.
Introduction
The filamentous soil bacteria, Streptomyces species,
are well known by a linear chromosome, complex mor-
phological differentiation, and an ability to produce
many bioactive secondary metabolites including antibi-
otics. A prominent class of secondary metabolites,
polyketides, contain important compounds for pharma-
ceutical and agrochemical uses such as erythromycin,
rapamycin, FK506, lovastatin, and avermectin [1]. In the
biosynthesis of polyketides, short chain carboxylic
acids are assembled and modified in a programmed
order by multifunctional polyketide synthases (PKSs).
These biosynthetic genes are intriguing targets for ge-
netic engineering to create rationally designed novel
polyketides.
Antibiotic biosynthetic genes in Streptomyces spe-
cies usually form a condensed gene cluster on the
chromosome. At this moment, however, three large lin-
ear plasmids coding an antibiotic gene cluster(s) are
known: SCP1 in Streptomyces coelicolor A3(2) carries
the methylenomycin biosynthetic genes [2–5]; pPZG103
in Streptomyces rimosus has the biosynthetic genes for
oxytetracycline [6]; and pSLA2-L in Streptomyces
rochei has those for lankamycin and lankacidin [7–10].
Streptomyces rochei strain 7434AN4 contains three
linear plasmids (pSLA2-L, -M, and -S), and produces
two structurally unrelated polyketide antibiotics, 17-*Correspondence: kinashi@hiroshima-u.ac.jpmembered macrocyclic lankacidins (Figure 1, lankaci-
din C, 1; lankacidinol A, 2) [11–13] and a 14-membered
macrolide lankamycin (3) [14]. Lankacidin antibiotics
exhibit significant antibacterial activities against a wide
variety of bacteria [15]. Lankacidin A (7-O-acetyl-lan-
kacidin C) is commercially used in livestock industries
for the treatment of porcine infected with Serpulina
(Treponema) hyodysenteriae, an anaerobic spirochete
[16]. Lankacidins also possess potent in vivo antitumor
activity against L1210 leukemia, etc. [17]. Therefore,
creation of novel lankacidin derivatives by gene modifi-
cation is important for pharmaceutical and agricultural
uses.
Correlation between the plasmid profiles and the an-
tibiotic production in the mutants derived from the par-
ent strain 7434AN4 suggested that the largest plasmid
pSLA2-L is involved in the production of both antibiot-
ics [7]. Southern hybridization analysis using eryAI and
actI revealed that pSLA2-L contained homologous re-
gions to these typical type I and type II PKS probes [8].
Targeting and partial sequencing experiments con-
firmed that two eryAI-homologous regions on PstI frag-
ment A (Figure 2A) are parts of a large type I PKS gene
cluster for lankamycin [9]. Finally, the lankacidin bio-
synthetic gene cluster has been identified by the com-
plete nucleotide sequencing of pSLA2-L [10].
It was found that pSLA2-L is a linear plasmid of
210,614 bp and carries 143 open reading frames
(ORFs). The most striking feature of pSLA2-L is that
three-quarters of its DNA are occupied by secondary
metabolism-related genes. Namely, it contains two type
I PKS gene clusters for lankacidin (lkc) and lankamycin
(lkm), a type II PKS gene cluster (roc), a carotenoid bio-
synthetic gene cluster (crt), and many regulatory genes
including the homologs of afsA, arpA, adpA, and strR
in the A-factor regulatory cascade in Streptomyces
griseus [18, 19].
In this paper, we delimited the range of the lkc gene
cluster by extensive gene disruption experiments. In
particular, we analyzed the disruptants of orf7, a pyrro-
loquinoline quinone (PQQ) biosynthetic gene and orf14,
an amine oxidase gene. Structural elucidation of an in-
termediate isolated from the latter disruptant and its
bioconversion to lankacidin C revealed a novel cycli-
zation mechanism to the 17-membered macrocyclic
skeleton. In addition, we proposed a possible gross
biosynthetic route to lankacidin, which hypothesizes a
modular-iterative mixed polyketide biosynthesis.
Results and Discussion
Location and Range of the Lankacidin Biosynthetic
(lkc) Gene Cluster
To locate the lkc gene cluster on pSLA2-L, we carried
out large deletion experiments using the ordered cos-
mid library. Cosmid C10 covers a 40.6 kb DNA (nt
11,258–51,820 of the pSLA2-L sequence, accession
number AB088224) extending over the PstI-E1, C, and
B regions (Figure 2A). Digestion of cosmid C10 with
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250Figure 1. Chemical Structures of Lankacidin C (1), Lankacidinol A (2), Lankamycin (3), and LC-KA05 (4), Produced by Streptomyces rochei
7434AN4 and its Disruptantslane II). PQQ is a novel prosthetic group of quinopro-orf20–22, which were disrupted simultaneously. As
Figure 2. PstI Fragment Map and Ordered
Cosmid Map of pSLA2-L and Organization of
the lkc Gene Cluster and its Flanking Re-
gions
(A) Fragment and cosmid map. The locations
of three terminal plasmids, Eco4, HindE, and
Eco3 [8] are also shown. Shadowed boxes
indicate the biosynthetic gene clusters for
lankacidin, lankamycin, an unknown type II
polyketide, and a carotenoid.
(B) lkc Gene Cluster. The lkc genes were
named in the leftward direction from lkcA
(orf18) to lkcO (orf4). Arrows indicate the
transcription direction of genes.BamHI and insertion of a kanamycin resistance gene s
(cassette [20] gave plasmid pTI-C02, which retained
only the left (1.3 kb) and right (2.5 kb) ends of the origi- b
tnal insert. Replacement of the vector part of pTI-C02
by the shuttle vector pRES18 [21] generated a targeting (
tplasmid pTI-C03. By using this plasmid for gene re-
placement, we succeeded in deleting a 36.8 kb DNA (nt h
g12,541–49,309) extending over orf12–orf30. An ob-
tained disruptant TI-C10 did not produce lankamycin or S
tlankacidin (Figure 3A, lane IV), which indicated that the
lkc gene cluster is located on the left side of the lkm T
Agene cluster.
To reveal what ORFs are included in the lkc cluster, l
dthe following ORFs were selected and subjected to gene
inactivation experiments (Table 1). The Orf3 protein has a f
iconsiderable similarity to StrR, a pathway-specific tran-
scriptional regulator in streptomycin biosynthesis [22]. c
aFive genes (orf4–orf8) form a gene cluster for the synthe-
sis of PQQ [23], a newly recognized vitamin necessary c
ffor oxidoreductases. The orf9 gene encodes an ATP
binding cassette (ABC) transporter. The orf18 gene en-
codes a PKS/NRPS fused protein, which was specu- P
Alated to be involved in the initial condensation reaction
of glycine and malonate. Orf19, Orf20, Orf21, and Orf22 t
tshow moderate similarities to dehydrogenase, tetracy-
cline-efflux transporter, peptide synthetase, and poly- W
tketide synthase, respectively.
These genes were separately inactivated except for chown in Figure 3A, disruptants of orf7 (lane V), orf9
lane VI), and orf18 (lane VII) did not produce lankacidin
ut produced lankamycin. On the other hand, disrup-
ants of orf3 (lane VIII), orf19 (lane IX), and orf20–22
lane X) produced both antibiotics. Against our expec-
ation, disruption of the regulatory gene, orf3, did not
ave an effect on antibiotic production, while the pqqC
ene (orf7) was necessary for lankacidin production.
ince orf4–orf8 form a pqq gene cluster, we concluded
hat the left border of the lkc cluster is located at orf4.
he result of the orf9 disruptant suggested that this
BC transporter functions in the self-resistance against
ankacidin. The PKS/NRPS fused gene (orf18) was in-
ispensable for lankacidin production, but none of the
our genes on its right side (orf19–orf22) were, delimit-
ng the right border at orf18. Therefore, the lkc gene
luster was deduced to contain 15 ORFs (orf4–orf18)
nd extend over 31.0 kb. The genes in the lkc gene
luster were named lkcA–lkcO in the leftward direction
rom orf18 to orf4 (Figure 2B and Table 1).
QQ Is Essential for Lankacidin Production
s described above, the pqq mutant FS7 (lkcL disrup-
ant) did not produce lankacidin. To confirm the func-
ion of PQQ, feeding experiments were performed.
hen PQQ was added to mutant FS7 at a final concen-
ration of 2 g/ml, the lankacidin production was re-
overed to the level of the wild-type strain (Figure 3B,
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251Figure 3. Analysis of Antibiotic Production by Bioautography and
HPLC
(A) Bioautography of S. rochei strain 51252 and its gene disrup-
tants. I, lankamycin; II, lankacidin C; III, strain 51252; IV, strain TI-
C10 (orf12-30); V, strain FS7 (lkcL); VI, strain FS9 (lkcJ); VII,
strain FS18 (lkcA); VIII, strain FS3 (orf3); IX, strain FS19 (orf19);
X, strain FS2022 (orf20-22); XI, strain KK23 (orf23); XII, strain
KA05 (lkcE). A lower inhibitory spot on lane III shows lankacidi-
nol A.
(B) Feeding effect of PQQ. I and II, the pqq mutant FS7 without and
with a feeding of PQQ.
(C) Bioconversion and cofermentation. I, strain KA05 containing
pKAR1023; II, strain FS7 fed with LC-KA05; III and IV, strain
KAFS13-1 without and with a feeding of LC-KA05; V, cofermentaion
of strains KA05 and FS7. The added thiostrepton gave an inhibitory
spot at the origin (lane I).
(D) HPLC analysis. I, strain 51252; II, strain KA05; III, strain FS7 fed
with LC-KA05. Lankacidin C (1), lankacidinol A (2), and LC-KA05 (4)
were eluted at 8.5, 16.9, and 22.1 min, respectively.teins [24, 25], which have been classified as the third
oxidoreductase family following well-known pyridine
dinucleotide- and flavin-dependent hydrogenases.
The lkc cluster and its flanking regions contain two
possible oxidoreductase genes; orf23, on the right sideof the cluster, is similar to a PQQ-dependent polyvi-
nylalcohol dehydrogenase gene, and lkcE (orf14) in the
middle of the cluster is similar to a flavin-dependent
amine oxidase gene. Lupanine hydroxylase from Pseu-
domonas sp., a member of the quinoprotein family, oxi-
dizes an amine moiety in lupanine to an imine, which is
then hydrated to give 17-hydroxy-lupanine [26]. There-
fore, we first speculated that Orf23 might function simi-
larly in the oxidation reaction of an amide at C-18 to an
imide in lankacidin biosynthesis. However, this was not
the case, because the orf23 disruptant produced both
lankacidin and lankamycin (Figure 3A, lane XI).
Acyclic Intermediate Produced by an Amine
Oxidase (lkcE) Mutant
In contrast to the orf23 mutant, an lkcE disruptant
(strain KA05) did not produce lankacidin but produced
lankamycin (Figure 3A, lane XII). The defect of this mu-
tant was complemented by introduction of a functional
copy of lkcE on pRES18 (Figure 3C, lane I). The LkcE
protein contains an FAD fingerprint motif, G-X-G-X-X-G,
at the N terminus [27]. Although no antibacterial activi-
ties were detected in the lankacidin fractions of gel
chromatography, a UV-absorbing compound was iso-
lated from mutant KA05. This compound was further
purified by silica gel chromatography to afford a white
powder, LC-KA05: C27H38NO8, m/z 504.2600 [M+-H],
calcd. 504.2598; λmax 237 nm ( 26,800) in ethanol;
[α]D25 +17.1 (c 0.57, ethanol).
The molecular formula of LC-KA05 indicates that it is
two hydrogens larger than lankacidinol A (C27H36NO8).
1H- and 13C-NMR data of lankacidin C (1), lankacidinol
A (2), and LC-KA05 are listed and compared in Table 2.
The latter two compounds showed 27 carbon signals,
two carbons more than 1, due to the presence of an
acetoxy group (C-26 and C-27). Comparison of their
DEPT spectra revealed that the tertiary carbon (C-2,
57.0 ppm) in 2 was changed to a methine carbon (50.2
ppm) in LC-KA05, and the methine carbon (C-18, 51.2
ppm) to a methylene carbon (37.1 ppm). In accordance
with these changes, the C-2 carbon of LC-KA05
showed a long-range coupling with the C-19 methyl
protons (1.35 ppm), but not with the C-18 methylene
protons (4.02 ppm) in HMBC experiments. From these
results, LC-KA05 was deduced to be an acyclic re-
duced compound of lankacidinol A, where the C2-C18
linkage is not present (Figure 1, compound 4).
The 1H- and 13C-NMR spectra of LC-KA05 did not
show any signals due to an enol form, indicating that
the β-keto-δ-lactone ring exists mainly as a ketonic
form. Irradiation of the C-2 proton gave a strong NOE
(13%) on the C-5 proton, whereas irradiation of the
overlapping methyl protons (C-19 and C-25) showed no
NOE. Thus, we assigned that the C-2 methyl is trans (α
configuration) to the C-5 proton.
To prove that LC-KA05 is a precursor of lankacidin,
bioconversion experiments were performed using non-
producing mutants, FS7 (pqq mutant) and KAFS13-1
(mutant of the lkcF-KR1 domain; KR, ketoreductase).
Bioautography clearly showed that LC-KA05 was con-
verted to lankacidin C in both cases (Figure 3C, lanes
II and IV). The bioconversion was also analyzed by a
reverse-phase HPLC, where lankacidin C (1), lankacidi-
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252Table 1. Deduced Functions of ORFs in the Lankacidin Biosynthetic Gene Cluster and Its Flanking Regions
Amino
Gene Acids Disruptant Similar protein (origin, accession number, identity/similarity) or PKS/NRPS domains
orf3 328 FS3 Transcriptional regulator (Streptomyces griseus StrR, Y00459, 46/58)
lkcO (orf4) 296 PQQ biosynthetic gene B (Pseudomonas aeruginosa PqqB, AE004625, 34/47)
lkcN (orf5) 364 PQQ biosynthetic gene E (Pseudomonas aeruginosa PqqE, AE004625, 46/56)
lkcM (orf6) 90 PQQ biosynthetic gene D (Pseudomonas aeruginosa PqqD, AE004625, 39/53)
lkcL (orf7) 242 FS7 PQQ biosynthetic gene C (Pseudomonas aeruginosa PqqC, AE004625, 49/61)
lkcK (orf8) 34 PQQ biosynthetic gene A (Sinorhizobium meliloti PqqA, AL603642, 39/57)
lkcJ (orf9) 545 FS9 ABC transporter (Streptomyces coelicolor A3(2), AL133424, 64/76)
lkcI (orf10) 569 ABC transporter (Streptomyces antibioticus OleB, L36601, 44/60)
lkcH (orf11) 184 Isochorismatase (Chromobacterium violaceum ATCC 12472, AAQ61295, 31/50)
lkcG (orf12) 926 Type I PKS: KS (11–418), ACP (589–656), TE (725–920)
lkcF (orf13) 2,346 KAFS13-1 Type I PKS: KR1 (198–359), ACP1 (456–524), KS1 (605–1020), KR2 (1392–1553), ACP2
(1659–1725), KS2 (1783–2191)
lkcE (orf14) 438 KA05 Amine oxidase (Agrobacterium tumefaciens Atu1977, AAL42972, 27/43)
lkcD (orf15) 293 Acyltransferase (Streptomyces atroolivaceus LnmG, AAN85520, 44/54)
lkcC (orf16) 1,862 Type I PKS: KR (231–392), MT (586–782), ACP1 (821–886), ACP2 (926–991), KS (1042–1456)
lkcB (orf17) 276 Dehydratase (Bacillus subtilis PksP-DH, E69679, 24/43)
lkcA (orf18) 1,622 FS18 PKS-NRPS hybrid: C (8–273), A (459–856), PCP (967–1024), KS (1063–1473)
orf19 499 FS19 Dehydrogenase (Archaeoglobus fulgidus MaoC, A69539, 45/72)
orf20 426 FS2022 Tetracycline-efflux transporter (Xanthomonas axonopodis TetA, AAM39125, 23/39)
orf21 84 FS2022 Peptide synthetase (truncated) (Streptomyces verticillus NRPS11-10, AF210249, 47/60)
orf22 517 FS2022 Polyketide synthase (Clostridium thermocellum Chte1256, ZP060858, 32/50)
orf23 543 KK23 PQQ-dependent dehydrogenase (Xanthomonas campestris XCC4080, AAM43301, 37/51)KA05 was cultured together with strain FS7, lankacidinthat LC-KA05 is a biosynthetic intermediate to lankaci-
Table 2. 1H- and 13C-NMR Data of Lankacidin C (1), Lankacidinol A (2), and LC-KA05 (4)
Lankacidin C (1) Lankacidinol A (2) LC-KA05 (4)
No. δC δH (J value in Hz) δC δH (J) δC δH (J )
1 169.9 (s) - 169.9 (s) - 169.1 (s) -
2 56.7 (s) - 57.0 (s) - 50.2 (d) 3.53 (q, 6.7)
3 210.9 (s) - 211.2 (s) - 203.8 (s) -
4 46.4 (d) 2.36–2.44 (m) 46.5 (d) 2.40–2.44 (m) 46.6 (d) 2.34 (m)
5 75.6 (d) 4.43 (dt, 11.9, 3.4) 75.3 (d) 4.40 (dt, 12.5, 3.7) 76.5 (d) 4.40 (dt, 2.7, 6.3)
6 36.7 (t) 2.28 (m) 34.3 (t) 2.21–2.35 (m) 37.4 (t) 2.05–2.15 (m)
7 69.9 (d) 4.33 (dt, 6.1, 9.8) 71.5 (d) 5.43 (dt, 5.2, 10.2) 71.9 (d) 5.64 (dt, 7.8, 8.0)
8 129.2 (d) 5.79 (dd, 9.5, 15.3) 124.5 (d) 5.70 (dd, 9.5, 15.3) 123.5 (d) 5.50 (dd, 7.8, 15.6)
9 138.2 (d) 6.14 (d, 15.3) 141.0 (d) 6.27 (d, 15.3) 139.3 (d) 6.41 (d, 15.6)
10 136.4 (s) - 136.2 (s) - 135.1 (s) -
11 128.6 (d) 5.31 (dd, 7.0, 9.5) 129.6 (d) 5.31 (dd, 6.7, 10.1) 129.9 (d) 5.59 (t, 7.3)
12 36.8 (t) 2.36–2.44 (m) 36.9 (t) 2.40–2.44 (m) 36.5 (t) 2.38–2.51 (m)
13 74.6 (d) 4.08 (dt, 5.5, 8.2) 74.6 (d) 4.09 (dt, 5.5, 8.2) 72.3 (d) 4.24–4.28 (m)
14 131.2 (d) 5.50 (dd, 8.2, 15.9) 131.0 (d) 5.49 (dd, 8.0, 15.6) 130.8 (d) 5.71 (dd, 6.7, 15.6)
15 134.6 (d) 5.59 (d, 15.9) 134.8 (d) 5.60 (d, 15.6) 134.6 (d) 6.25 (d, 15.9)
16 139.4 (s) - 139.0 (s) - 136.1 (s) -
17 124.2 (d) 4.67 (d, 10.7) 125.0 (d) 4.68 (d, 11.0) 127.4 (d) 5.49 (m)
18 51.8 (d) 5.40 (t, 10.7) 51.2 (d) 5.54 (t, 10.4) 37.1 (t) 4.02 (dd, 7.3, 13.4)
19 20.9 (q) 1.38 (s) 20.9 (q) 1.41 (s) 7.9 (q) 1.35 (d, 6.4)
20 9.6 (q) 1.26 (d, 6.7) 9.4 (q) 1.30 (d, 6.7) 12.3 (q) 1.21 (d, 7.5)
21 12.7 (q) 1.55 (s) 12.5 (q) 1.55 (s) 12.7* (q) 1.77 (s)
22 12.9 (q) 1.91 (s) 12.9 (q) 1.90 (s) 12.6* (q) 1.81 (s)
23 159.7 (s) - 173.7 (s) - 174.0 (s) -
24 196.5 (s) - 68.5 (d) 4.24 (q, 6.7) 68.5 (d) 4.25 (q, 6.7)
25 24.5 (q) 2.47 (s) 21.5* (q) 1.38 (d, 6.7) 21.4* (q) 1.35 (d, 6.7)
26 - - 170.2 (s) - 170.1 (s) -
27 - - 21.4* (q) 2.04 (s) 21.3* (q) 2.07 (s)
N-H - 8.09 (d, 9.8) - 7.53 (d, 10.1) - 6.54 (br)
Carbons with an asterisk are exchangeable.nol A (2), and LC-KA05 (4) were separated well (Figure d
i3D, columns I and II). Most of the added LC-KA05 was
converted to lankacidin C by mutant FS7, although i
Lsmall amounts of LC-KA05 and lankacidinol A were de-
tected (Figure 3D, column III). These results confirmed pin. At the same time, it was suggested that PQQ is not
nvolved in the oxidation process of an amide to an im-
de, because the pqq mutant FS7 was able to convert
C-KA05 to lankacidin C. This speculation was sup-
orted by a cofermentation experiment; when strain
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253production was restored (Figure 3C, lane V). Therefore,
it has not yet been clarified how PQQ functions in lan-
kacidin biosynthesis.
Macrocyclization Mechanism
to the Lankacidin Skeleton
Based on the results described above, we propose a
cyclization mechanism for the synthesis of the lankaci-
din skeleton (Figure 4). Namely, the amide intermediate
(4) is first oxidized by the amine oxidase (LkcE) to an
imide (5), a protonated form of which in turn accepts
the nucleophilic attack of an enolate ion at C-2 to give
the 17-membered lankacidinol A (2). Oxidation of a hy-
droxyl group at C-24 and cleavage of an acetyl group
at C-7 are necessary for the conversion of 2 to lankaci-
din C (1), although the timing of these reactions is un-
known.
Previous feeding experiments of [2H5]- and [1-13C]gly-
cine into lankacidin showed that the deuterium on
C-18 was totally lost in contrast to a considerable in-
corporation of 13C into C-17 [28]. To explain this result,
a cyclopropanone intermediate consisting of C-1, C-2,
and C-18 was proposed, which was then converted to
the lankacidin skeleton by Favorskii-type rearrange-
ment. This rearrangement was also suggested for en-
terocin biosynthesis [29]. However, the present work
indicated this possibility was unlikely in lankacidin syn-
thesis. Our preliminary experiment using 13C-labeled
serine suggested that glycine-hydroxymethyl transfer-
ase might catalyze the equilibrium between glycine and
serine, leading to a complete loss of deuterium at C-18
(data not shown).
The novel cyclization mechanism revealed by this
work has a significant meaning, because amides and
1,3-diketones are common in PKS/NRPS hybrid com-
pounds; therefore, amine oxidases like LkcE have a po-
tential to create novel macrocyclic compounds with
various molecular architectures and ring sizes in engi-
neered biosynthesis.
Possible Biosynthetic Route to Lankacidin
Gene inactivation experiments in this study delimited
the range of the lkc gene cluster from lkcA to lkcO. A
comprehensive view of the predicted functions of the
lkc genes (Table 1) and the structural characteristics of
lankacidin led us to propose a possible gross biosyn-
thetic route to lankacidin (Figure 5), which is explained
below.
The carbon skeleton of lankacidin is synthesized
from a starter glycine molecule and eight malonate
molecules [30]. All the methyl groups at C-2, C-4, C-10,Figure 4. Macrocyclization Mechanism for
the Synthesis of the Lankacidin Skeleton
The hypothetical intermediate (5) in a bracket
has not been isolated.and C-16 are not derived from propionate but from me-
thionine by C-methylation. In accordance with these re-
sults, lkcA, the first PKS gene in the cluster, encodes a
fusion protein of PKS and NRPS. PKS/NRPS hybrids
have been found in many biosynthetic gene clusters
from Streptomyces, Xanthomonas, cyanobacterium,
and even beetles [31]. The NRPS region of LkcA has
domains for condensation, adenylation and thiolation
(PCP; peptidyl carrier protein), while the PKS region
possesses only a ketosynthase (KS) domain. The ade-
nylation domain contains amino acid residues, DILQTL-
VEAK, at the positions of 235, 236, 239, 278, 299, 301,
322, 330, 331, and 517 (nt 33,131-33,979) [32] for gly-
cine recognition.
An interesting feature of the lkc-PKSs is that they do
not have a linear relationship with condensation reac-
tions, which is different from usual modular-type PKSs.
However, in the last few years, similar type I PKS sys-
tems without a colinearity have been reported; for in-
stance, the biosynthetic gene clusters for lovastatin
[33], leinamycin [34], C-1027 [35], calicheamicin [36],
borrelidin [37], and albicidin [38].
The fused PKS/NRPS (LkcA) and the three lkc-PKSs
(LkcC, LkcF, and LkcG) have a total of five KS domains,
although the lankacidin skeleton requires eight conden-
sation events. Additional type I PKS genes (orf56-orf61)
were found in the center of pSLA2-L, disruption of
which however gave no effect on lankacidin synthesis
(data not shown). Thus, we hypothesized that LkcC cat-
alyzes iteratively four chain elongation reactions. In this
respect, it is noteworthy that LkcC carries two tan-
demly aligned ACP domains; similar domains were sug-
gested to be involved in iterative condensations in al-
bicidin synthesis [38]. The discrete acyltransferase (AT,
LkcD) and dehydratase (DH, LkcB), and also the
methyltransferase (MT) domain in LkcC may act itera-
tively in trans on each biosynthetic intermediate. In
contrast, LkcA, LkcF, and LkcG may function modularly
in the first and the last two condensation reactions.
This modular-iterative mixed biosynthesis completely
agrees with the chemical structure of lankacidin. To
prove this hypothesis, we are now constructing point
mutants of the three KR domains (lkcC-KR, lkcF-KR1,
and lkcF-KR2), which are expected to accumulate cru-
cial intermediates.
Another possibility that missing modules are fed by
the adjacent lkm gene cluster was denied by disruption
of lkmAI, which gave no effect on lankacidin production
[9]. However, an additional possibility that missing
modules are located on the chromosome has not been
ruled out. Heterologous expression of the whole lkc
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254Figure 5. Possible Gross Biosynthetic Route
to Lankacidin
R, CH3-C(=O)C(=O)- or CH3-CH(OH)C(=O)-;
KS, β-ketoacyl-ACP synthase; ACP, acyl car-
rier protein; TE, thioesterase; KR, β-keto-
acyl-ACP reductase; AT, acyltransferase; MT,
C-methyltransferase; DH, β-hydroxy-acyl-
ACP dehydratase; C, condensation domain;
A, adenylation domain; PCP, peptidyl carrier
protein.3gene cluster will give a final answer to this question,
rwhich is also in progress. The thioesterase (TE) domain
in LkcG may catalyze the formation of a δ-lactone ring
Din place of a usual macrolide ring to give LC-KA05 (4),
Dwhich is finally converted to the macrocylic lankacidin
f
C (1) by the mechanism described above. t
r
sSignificance
m
hThe range of the lankacidin biosynthetic (lkc) gene
p
cluster on the giant linear plasmid pSLA2-L has been M
delimited by precise gene inactivation experiments e
eand analysis of metabolites of the disruptants. The
Clkc-PKSs have two unique characteristics, cyclization
oto a macrocyclic skelton and no colinearity
obetween modules and condensation reactions. Con-
cerning the first characteristic, we revealed a cycliza- s
tion mechanism where an amine oxidase (LkcE) oxi- k
sdizes the acyclic amide intermediate (LC-KA05) to an
Himide, which in turn is converted to the 17-membered
tlankacidin skeleton. This result has opened a way to
create “unnatural natural” polyketide compounds
Awith a macrocyclic skeleton. For the second charac-
Oteristic, we proposed a hypothesis in which LkcC iter-
i
atively functions four times, which enables the five f
KS domains in the lkc-PKSs to accomplish eight con- w
cdensation reactions. Thus, the lkc-PKSs may be a
lmixture of modular and iterative PKSs.
o
wExperimental Procedures
i
tStrains and Culture Conditions
1S. rochei strain 51252 [7] carrying only pSLA2-L was used to con-
mstruct various lkc gene disruptants. All the gene disruptants con-
Mstructed in this study are listed in Supplemental Table S1 (Supple-
mental Data). For DNA preparation, Streptomyces strains were
grown in YEME liquid medium [39] (0.3% yeast extract, 0.5% poly- I
Tpepton, 0.3% malt extract, 1% D-glucose, 34% sucrose, 5 mM
MgCl2, and 0.25% glycine). E. coli XL1-Blue was used for routine (
kcloning and construcion of targeting plasmids. E. coli strains were
grown in Luria Bertani (LB) medium supplemented with ampicillin i
c(100 g/ml). YMG medium (0.4% yeast extract, 1.0% malt extract,
and 0.4% glucose, pH 7.3) and TSB medium (tryptic soy broth, y0 g per liter) were used for antibiotic production and bioassay,
espectively.
NA Manipulation and Gene Inactivation
NA manipulations for Streptomyces [39] and E. coli [40] were per-
ormed according to standard procedures. pRES18, a shuttle vec-
or containing a thiostrepton resistant gene [21] and a kanamycin
esistance gene cassette [20], were used for gene disruption. Con-
truction procedures of targeting vectors are described in Supple-
ental Data. They were propagated in E. coli ET12567 (dam, dcm,
sdM) [41] and transformed into S. rochei 51252. Streptomyces
rotoplasts were regenerated on R1M plates [42] (K2SO4, 0.25 g;
gCl2·6H2O, 4.07 g; casamino acids, 0.1 g; L-asparagine, 2 g; yeast
xtract, 8 g; polypepton, 5 g; glucose, 10 g; sucrose, 103 g; trace
lement solution, 2 ml; 5.73% TES (pH 7.3), 100 ml; 7.37%
aCl2·2H2O, 100 ml; KH2PO4, 10 ml; and 2% agar per liter) and then
verlaid with soft agar containing thiostrepton (final concentration
f 10 g/ml).
Thiostrepton-resistant colonies were picked up and subjected to
uccessive liquid cultures in YEME medium containing 10 g/ml of
anamycin to facilitate a double crossover. All the disruptants were
ubjected to Southern blot analysis to confirm a double crossover.
ybridization was carried out using DIG DNA labeling and a detec-
ion kit (Roche) according to the manufacturer’s protocol.
ntibiotic Production and Bioautography
ne milliliter of the full-grown precultures of S. rochei strains were
noculated into 100 ml of YMG liquid medium in a 500 ml Sakaguchi
lask and reciprocally cultured at 28°C for 3 days. The broth filtrates
ere extracted with ethyl acetate, dehydrated with Na2SO4, and
oncentrated to crude extracts. The extracts were applied to thin
ayer chromatography (TLC) (Kieselgel 60 F254, Merck) and devel-
ped with chloroform-methanol (15:1). The developed TLC plate
as dried and contacted with a bioassay plate for 30 min, and
ncubated at 28°C overnight. The bioassay plate was composed of
wo layers; the bottom layer contained TSB medium containing
.5% agar, while the top layer contained TSB-agar (0.8%) supple-
ented with 2% of the overnight culture of the indicator organism,
icrococcus luteus.
solation and Analysis of Metabolites
he crude extract was applied to Sephadex LH-20 chromatography
1 × 40 cm, Amersham Pharmacia Biotech AB) with methanol. Lan-
amycin was eluted in 20–25 ml fractions, while lankacidins were
n 28–34 ml. The latter fractions were further purified by silica gel
hromatography with chloroform-methanol (50:1–20:1). Average
ields of lankacidin C (1) and lankacidinol A (2) from the parent
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255strain 51252 were 8.0 and 0.5 mg per liter, respectively. The yield
of compound LC-KA05 (4) from strain KA05 was 1.5 mg per liter.
Lankacidins and LC-KA05 were also analyzed by HPLC. The
crude extract was applied on a TSKgel ODS-80Ts column (5 m
diameter, 4.6 × 250 mm; Tosoh, Tokyo), eluted with a mixture (3:1)
of acetonitrile and 10 mM sodium phosphate (pH 8.2) at a flow rate
of 1 ml/min, and monitored by a Jasco MD-2010 multiwavelength
detector.
Feeding, Complementaion, Bioconversion,
and Cofermentaion Experiments
Feeding of PQQ
Two hundred micrograms of PQQ was added to a 100 ml YMG
culture of the pqqmutant FS7 at 24 hr and the culture was stopped
and analyzed at 72 hr.
Complementation of the lkcE Mutation
Plasmid pKAR1023, which contained a functional lkcE gene on
pRES18 (see Supplemental Data), was transformed into the lkcE
mutant KA05. The transformant was cultured in YMG medium at
28°C for 72 hr in the presence of 10 g/ml of thiostrepton.
Bioconversion of LC-KA05
1.0 milligram of LC-KA05 was added at 24 hr to 100 ml YMG cul-
tures of strains FS7 and KAFS13-1, respectively, and the fermenta-
tion was stopped and analyzed at 72 hr.
Cofermentation Experiment
Strains KA05 and FS7 were mixed cultured in YMG medium at 28°C
for 72 hr.
Spectroscopic Instruments
Nuclear magnetic resonance (NMR) spectra were recorded on a
Jeol LA-500 spectrometer equipped with a field-gradient acces-
sory. Deuteriochloroform (99.8 atom %) was used as NMR solvent.
1H NMR and 13C NMR chemical shifts were recorded in δ values
based on the signals of tetramethylsilane (TMS) (δH = 0) and CDCl3
(δC = 77.0), respectively. Whole correlations in the lankacidin frame-
work were determined by several 2D-NMR spectra (DQF-COSY,
HMQC, and HMBC). The high-resolution FAB-MS spectra were
monitored on a Jeol SX-102A mass spectrometer.
Supplemental Data
The construction procedures of all the gene disruptants and their
Southern hybridization analysis as well as spectroscopic data of
compounds 1, 2, and 4 are available at http://www.chembiol.com/
cgi/content/full/12/2/249/DC1.
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